PetrosConstantineKarakousisMD

PubMed

• Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ ...
  Kaitlyn Fessler, Jiaqi Zhang, Avinaash K Sandhu, Yinan Hui, Aakanksha R Kapoor
  Journal of Immunotherapy. 2025-01-01
• Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve Mycobacterium tuberculosis control in infected mice.
  Jennie Ruelas Castillo, Valentina Guerrini, Darla Quijada, Styliani Karanika, Pranita Neupane
  The Journal of Infectious Diseases. 2024-11-19
• Bystander monocytic cells drive infection-independent NLRP3 inflammasome response to SARS-CoV-2.
  Leon L Hsieh, Monika Looney, Alexis Figueroa, Guido Massaccesi, Georgia Stavrakis
  Mbio. 2024-10-16

Journal Articles

• Genome analysis of Mycobacterium avium subspecies hominissuis strain 109  
  Matern WM, Bader JS, Karakousis PC, Sci Data, 1/1/2018
• Unprecedented in Vitro Antitubercular Activitiy of Manganese(II) Complexes Containing 1, 10-Phenanthroline and Dicarboxylate Ligands: Increased Activity, Superior Sele...  
  McCarron P, McCann M, Devereux M, Kavanagh K, Skerry C, Karakousis PC, Aor AC, Mello TP, Santos ALS, Campos DL, Pavan FR, Front Microbiol, 1/1/2018
• Gene enrichment analysis reveals major regulators of Mycobacterium tuberculosis gene expression in two models of antibiotic tolerance  
  Matern WM, Rifat D, Bader J, Karakousis PC, Front Microbiol, 1/1/2018
• Altered Mycobacterium tuberculosis cell wall metabolism and physiology associated with RpoB mutation H526D  
  Campodonico VL, Rifat D, Chuang Y-M, Ioerger TR, Karakousis PC, Front Microbiol, 1/1/2018
• Intranasal immunization with DnaK protein induces protective mucosal immunity against tuberculosis in CD4-depleted mice  
  Chuang Y-M, Pinn ML, Karakousis PC, Hung C-F, Front Cell Infect Microbiol, 1/1/2018
• Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment  
  Degner NR, Wang J-Y, Golub JE, Karakousis PC, Clin Infect Dis, 1/1/2018
• In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D  
  Rifat D, Campodonico VL, Tao J, Miller JA, Alp A, Yao Y, Karakousis PC, Antimicrob Agents Chemother, 1/1/2017
• Development of a novel lead that targets M tuberculosis polyketide synthase 13  
  Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, Dutta NK, Galaviz S, Dhakal RC, Shrestha, R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion..., Cell, 1/1/2017
• Empirical Antifungal Therapy in Critically Ill Patients With Sepsis: Another Case of Less Is More in the ICU  
  Siddharthan T, Karakousis PC, Checkley W, JAMA (Journal of the American Medical Association), 1/1/2016
• Statin adjunctive therapy shortens the duration of TB treatment in mice  
  Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, Gennaro ML, Karakousis PC, J Antimicrob Chemother, 1/1/2016
• Identification of a transcription factor that regulates host cell exit and virulence of Mycobacterium tuberculosis  
  Srinivasan L, Gurses SA, Hurley BE, Miller JL, Karakousis PC, Briken V, PLoS Pathog, 1/1/2016
• First evaluation of GenoType MTBDRPlus 20 performed directly on respiratory specimens in Central America  
  Lanzas F, Ioerger TR, Shah H, Acosta W, Karakousis PC, J Clin Microbiol, 1/1/2016
• Mycobacterial protein tyrosine phosphatases A and B inhibitors augment the bactericidal activity of standard anti-TB regimen  
  Dutta NK, He R, Pinn ML, He Y, Burrows F, Zhang Z-Y, Karakousis PC, ACS Infect Dis, 1/1/2016
• The stringent response factors PPX1 and PPK2 play an important role in Mycobacterium tuberculosis metabolism, biofilm formation, and sensitivity to isoniazid in vivo  
  Chuang Y-M, Dutta NK, Hung CF, Wu TC, Rubin H, Karakousis PC, Antimicrob Agents Chemother, 1/1/2016
• Pleuropulmonary Kaposi Sarcoma in the Setting of Immune Reactivation  
  Suresh K, Semaan R, Arias S, Karakousis P, Lee H, J Pulm Respir Med, 1/1/2016
• A Tuberculosis Ontology for Host Systems Biology  
  Levine DM, Dutta NK, Eckels J, Scanga C, Stein C, Mehra S, Kaushal D, Karakousis PC, Salamon H, Tuberculosis (Edinb), 1/1/2015
• Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?  
  Dutta NK, Karakousis PC, Front Microbiol, 1/1/2015
• Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance and therapeutic alternatives  
  Via L, Savic R, Weiner D, Zimmerman M, Prideaux B, Irwin S, O'Brien P, Gopal P, Eum S, Lee M, Lanoix J-P, Lyon E, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenae..., ACS Infect Dis, 1/1/2015
• Differential expression of miRNAs and their relation to active tuberculosis  
  Xu Z, Zhou A, Ni J, Wang Y, Lu J, Karakousis PC, Lu S, Yao Y, Tuberculosis (Edinb), 1/1/2015
• Metabolomics specificity of tuberculosis plasma revealed by (1)H NMR spectroscopy  
  Zhou A, Ni J, Xu Z, Wang Y, Zhang H, Wu W, Lu S, Karakousis PC, Yao Y-F, Tuberculosis (Edinb), 1/1/2015
• Replication of Mycobacterium tuberculosis in Retinal Pigment Epithelium  
  Nazari H, Karakousis PC, Rao NA, JAMA Ophthalmol, 1/1/2014
• Latent tuberculosis infection: Myths, models, and molecular mechanisms  
  Dutta NK, Karakousis PC, Microbiol Mol Biol Rev, 1/1/2014
• Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice  
  Dutta NK, Illei P, Jain S, Karakousis PC, Am J Pathol, 1/1/2014
• Differential regulation of the two-component regulatory system senX3-regX3 in Mycobacterium tuberculosis  
  Rifat D, Karakousis PC, Microbiology, 1/1/2014
• Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis  
  Dutta NK, Pinn ML, Karakousis PC, Antimicrob Agents Chemother, 1/1/2014
• Join now to see all

Books/Book Chapters

• Handbook of Tuberculosis 
  Chapter: Clinical Features and Diagnosis of Tuberculosis: Primary Infection and Progressive Pulmonary Tuberculosis 
  Page 17 - 34Karakousis PC, Dutta NK, Manabe YCEditors: Grosset JH, Chaisson RE.Springer International Publishing, Switzerland2017
• Tuberculosis, Leprosy and Mycobacterial Diseases of Man and Animals: The Many Hosts of Mycobacteria 
  Chapter: Rabbit Model of Mycobacterial Diseases 
  Page 402 - 418Subbian S, Karakousis PC, Kaplan GEditors: Mukundan H, et al.CAB International2015
• Mycobacterium Tuberculosis/Book 2 
  Chapter: Old and New TB Drugs: Mechanisms of Action and Resistance 
  Kolyva A, Karakousis PCEditors: Cardona P-J.InTech2011
• Antimicrobial Drug Resistance 
  Chapter: Mechanisms of Action and Resistance of the Antimycobacterial Agents 
  Page 271 - 291Karakousis PCEditors: Mayers D,.Humana Press, New York2009
• Fishman's Pulmonary Diseases and Disorders 
  Chapter: Mycobacterial infections and HIV infection. 
  Page 2487 - 2497Karakousis PC, Chaisson REEditors: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI.McGraw Hill, New YorkEdition 4th,2008
• Join now to see all

Lectures

• "Overview of Tuberculosis" 
  1/1/2019
• "Animal models of TB infection." 
  1/1/2019
• "Tuberculosis and Antimicrobials" 
  JHUSOM (Johns Hopkins University School of Medicine), 2012-2019 - 1/1/2019
• "Classic Papers on Tuberculosis" 
  1/1/2019
• "Tuberculosis-Clinical Considerations" 
  1/1/2019
• "Advancing Host-Directed Therapies for Tuberculosis" 
  The Hague, Netherlands - 1/25/2018
• "Statins for TB: Can we harness the host?" 
  Newark, NJ - 1/20/2018
• "Inhibiting the Mtb Stringent Response: The Krotalon for Rousing Persisters?" 
  Baltimore, MD - 1/15/2018
• "What can 'omics tell us about TB reactivation risk in HIV-infected and uninfected adults and children?" 
  Rockville, MD - 1/2/2018
• "Novel strategies to detect and target Mtb persisters." 
  Silver Spring, MD - 1/28/2017
• "Strategic Discussion on Repurposing Drugs for TB" 
  Lucca, Italy - 1/27/2017
• "Tuberculosis Disease: Host Response and Diagnostics" 
  Washington, DC - 1/21/2017
• "Statins as Adjunctive, Host-Directed Therapy for Tuberculosis" 
  Athens, Greece - 1/21/2016
• "Tuberculosis: Susceptibility and Immune Response" 
  San Francisco, CA - 1/16/2016
• "Lessons Learned from the NHLBI-Sponsored Tuberculosis Systems Biology Program" 
  San Francisco, CA - 1/15/2016
• "Updates on Tuberculosis from CROI 2016" 
  Florence, Italy - 1/15/2016
• "Novel Approaches to Understanding and Combating Latent TB Infection" 
  San Francisco, CA - 1/15/2016
• "Novel Paradigms to Treat TB." 
  Baltimore, MD - 1/10/2016
• "Genetic and chemical validation of RelMtb as a target for M. tuberculosis persisters." 
  New York, NY - 1/28/2015
• "Mycobacterium tuberculosis: Molecular Basis of Persistence" 
  New Delhi, India - 1/23/2015
• "A Novel 'Shock and Kill' Strategy for Targeting Mtb Persisters." 
  Rockville, MD - 1/16/2015
• "Novel approaches to target Mycobacterium tuberculosis persisters." 
  Rockville, MD - 1/16/2015
• "Host directed therapies and biomarkers for TB." 
  Pune, India - 1/5/2015
• "Clinical Mycology" 
  1/1/2015
• "Latent TB Infection: Myths, Models, and Molecular Mechanisms" 
  Baltimore, MD - 1/31/2014
• Join now to see all

Other

• "XDR-TB Scare" 
  Karakousis PC, Fox National News (11:00 AM, Thursday)
  1/31/2007
• Greetings from sunny (most of the time) San Diego: Highlights from the 41st Annual Meeting of the Infectious Diseases Society of America. 
  Karakousis PC, Page KR, Bishai WR, JHU (Johns Hopkins University)Antibiotic Guide Website
  http://hopkins-abxguide.org
  1/1/2003
• Synopsis of key presentations at the 40th Annual Meeting of IDSA (October 24-27, 2002, Chicago). 
  Karakousis PC, Bishai WR, JHU (Johns Hopkins University)Antibiotic Guide Website
  http://hopkins-abxguide.org
  1/1/2002